Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Cardiovascular and Neurological Outcomes in Patients Treated with Edoxaban for Atrial Fibrillation and Characteristics in Patients with Cancer

Kai-Hung Cheng, Hung-Pin Tu, Kai-Chun Cheng, View ORCID ProfileMarielle Scherrer-Crosbie, Ting-Yuan Hsu
doi: https://doi.org/10.1101/2023.10.25.23297577
Kai-Hung Cheng
1Preventive Medical Center, Kao-Ho Hospital, Kaohsiung, Taiwan
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kaihung0218{at}gmail.com
Hung-Pin Tu
2Department of Public Health and Environmental Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kai-Chun Cheng
3Department of Ophthalmology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marielle Scherrer-Crosbie
4Cardiac Ultrasound Laboratory, Division of Cardiology, Hospital of the University of Pennsylvania.
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marielle Scherrer-Crosbie
Ting-Yuan Hsu
1Preventive Medical Center, Kao-Ho Hospital, Kaohsiung, Taiwan
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

BACKGROUND Direct oral anticoagulants (DOACs) outperform warfarin in vascular and bleeding events in atrial fibrillation (AF) patients. Yet, effects of DOACs on congestive heart failure (CHF) and Alzheimer’s disease (AD) remain less explored.

METHODS Using the Taiwan National Health Insurance Research Database, a nationwide retrospective cohort study was conducted. The study matched 5,683 non-valvular atrial fibrillation (NVAF) edoxaban patients with 11,366 warfarin patients, and 703 NVAF with cancer (NVAF-C) edoxaban patients with 1,406 warfarin patients. Vasular and non-vascular outcomes, with focuses on CHF and AD, were compared between the edoxaban and warfarin users.

RESULTS Edoxaban significantly lowered adjusted hazrad ratio (aHR) of all-cause mortality, hospitalization for gastrointestinal bleeding, and CHF (0.37, 0.74, and 0.26, respectively, in NVAF; 0.39, 0.67, and 0.31, respectively, in NVAF-C, all p < 0.05), compared to warfarin. Edoxaban was associated with significantly lower aHRs of acute myocardial infarction, peripheral artery disease, venous thromboembolism, pulmonary embolism, and AD (0.71, 0.48, 0.55, 0.20, and 0.66, respectively; all p < 0.05) in NVAF patients versus warfarin. However, edoxaban had higher aHR of hospitalized bleeding (1.19, p = 0.002) than warfarin in NVAF patients, but not in NVAF-C patients.

CONCLUSIONS Edoxaban demonstrated lowered CHF risks in both NVAF and NVAF-C patients, and reduced AD occurrence in NVAF patients versus warfarin. These findings advocate for edoxaban’s use in AF cases.

What Is New?The study reveals that in patients with atrial fibrillation (AF), edoxaban, a direct oral anticoagulant (DOAC), demonstrates significant advantages over warfarin. Notably, edoxaban is associated with a reduced risk of congestive heart failure (CHF) and Alzheimer’s disease (AD) when compared to warfarin.

Clinical Implications?These findings have important clinical implications. Edoxaban appears to be a superior anticoagulant choice for AF patients, as it lowers the risk of CHF and AD. This highlights the potential of edoxaban to improve patient outcomes and underscores its relevance for managing AF cases.

Competing Interest Statement

The study was supported by Daiichi Sankyo Taiwan Ltd. MS-C has received grant funding from NIH (grant number NIH-NHLBI R01HL130539). All authors have nothing else to be disclosed.

Clinical Trial

N/A

Funding Statement

The study was supported by Daiichi Sankyo Taiwan Ltd and NIH-NHLBI R01HL130539 (to MS-C).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study complied with the Declaration of Helsinki, with ethical approval from the Institutional Research Ethics Committee of Kaohsiung Medical University Hospital (IRB Number: KMUHIRB-EXEMPT(II)-21090039)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data availability & Supplementary material

Data are available in the article and its online Supplementary material. Hung-Pin Tu had full access to all the data in the study and takes responsibility for its integrity and the data analysis. The deidentified participant data will not be shared.

  • Nonstandard Abbreviations and Acronyms

    AF
    Atrial Fibrillation
    CHF
    Congestive Heart Failure
    AD
    Alzheimer’s Disease
    DOACs
    Direct Oral Anticoagulants
    NVAF
    Non-Valvular Atrial Fibrillation
    NHIRD
    National Health Insurance Research Database
    LMWHs
    Low-Molecular-Weight Heparins
    FXa
    Factor Xa
    PARs
    Proteinase Activated Receptors
    RAAS
    Renin-Angiotensin-Aldosterone System
    AMI
    Acute Myocardial Infarction
    PCI
    Percutaneous Coronary Intervention
    CKD
    Chronic Kidney Disease
    VTE
    Venous Thromboembolism
    PE
    Pulmonary Embolism
    AKI
    Acute Kidney Injury
    ICD-9-CM
    International Classification of Diseases, 9th Revision, Clinical Modification
    ICD-10-CM
    International Classification of Diseases, 10th Revision, Clinical Modification
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted October 26, 2023.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Cardiovascular and Neurological Outcomes in Patients Treated with Edoxaban for Atrial Fibrillation and Characteristics in Patients with Cancer
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Cardiovascular and Neurological Outcomes in Patients Treated with Edoxaban for Atrial Fibrillation and Characteristics in Patients with Cancer
    Kai-Hung Cheng, Hung-Pin Tu, Kai-Chun Cheng, Marielle Scherrer-Crosbie, Ting-Yuan Hsu
    medRxiv 2023.10.25.23297577; doi: https://doi.org/10.1101/2023.10.25.23297577
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Cardiovascular and Neurological Outcomes in Patients Treated with Edoxaban for Atrial Fibrillation and Characteristics in Patients with Cancer
    Kai-Hung Cheng, Hung-Pin Tu, Kai-Chun Cheng, Marielle Scherrer-Crosbie, Ting-Yuan Hsu
    medRxiv 2023.10.25.23297577; doi: https://doi.org/10.1101/2023.10.25.23297577

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Cardiovascular Medicine
    Subject Areas
    All Articles
    • Addiction Medicine (349)
    • Allergy and Immunology (668)
    • Allergy and Immunology (668)
    • Anesthesia (181)
    • Cardiovascular Medicine (2648)
    • Dentistry and Oral Medicine (316)
    • Dermatology (223)
    • Emergency Medicine (399)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
    • Epidemiology (12228)
    • Forensic Medicine (10)
    • Gastroenterology (759)
    • Genetic and Genomic Medicine (4103)
    • Geriatric Medicine (387)
    • Health Economics (680)
    • Health Informatics (2657)
    • Health Policy (1005)
    • Health Systems and Quality Improvement (985)
    • Hematology (363)
    • HIV/AIDS (851)
    • Infectious Diseases (except HIV/AIDS) (13695)
    • Intensive Care and Critical Care Medicine (797)
    • Medical Education (399)
    • Medical Ethics (109)
    • Nephrology (436)
    • Neurology (3882)
    • Nursing (209)
    • Nutrition (577)
    • Obstetrics and Gynecology (739)
    • Occupational and Environmental Health (695)
    • Oncology (2030)
    • Ophthalmology (585)
    • Orthopedics (240)
    • Otolaryngology (306)
    • Pain Medicine (250)
    • Palliative Medicine (75)
    • Pathology (473)
    • Pediatrics (1115)
    • Pharmacology and Therapeutics (466)
    • Primary Care Research (452)
    • Psychiatry and Clinical Psychology (3432)
    • Public and Global Health (6527)
    • Radiology and Imaging (1403)
    • Rehabilitation Medicine and Physical Therapy (814)
    • Respiratory Medicine (871)
    • Rheumatology (409)
    • Sexual and Reproductive Health (410)
    • Sports Medicine (342)
    • Surgery (448)
    • Toxicology (53)
    • Transplantation (185)
    • Urology (165)